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Abstract
Background: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART)
programmes in developing countries are not clearly defined.
Methods: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological
outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400
copies/ml.
Results: Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953
(81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 106/l). 71% (681/
953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal
virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence
interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001–
100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92–
6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage
1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment
for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported
100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log
decrease in viral load.
Conclusion: Virological response at six weeks after ART start was the strongest predictor of suboptimal virological
outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self
reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks.
Site of delivery had an important influence on virological outcomes; factors at the health system level which influence
outcome need further investigation to guide development of effective ART programmes.
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An unprecedented effort by global organisations, govern-
ments and health care workers has achieved access to
antiretroviral treatment (ART) for 2.0 million HIV-
infected individuals in low- and middle-income countries
by December 2006. Despite these efforts, 72% of the esti-
mated 7.1 million who need ART globally are not on treat-
ment, and hence strategies to improve access to care for
HIV-infected persons have been the subject of much dis-
cussion [1,2]. As more patients start ART, treatment pro-
grammes face the emerging challenge of achieving and
maintaining virological suppression in increasing num-
bers of patients for sustained periods. Treatment success
requires excellent adherence to ART, which is difficult to
maintain [3]. A suboptimal virological response to ART
may lead to increased transmission of ART-resistant virus
strains and ultimately to a dramatic reduction of the ther-
apeutic lifespan of available ART regimens [4-6].
ART programmes in developing countries have reported
varied treatment outcomes. Pilot projects established by
non-governmental organisations in South Africa and
Haiti have reported good virological results [7-9]
although others have been less encouraging [10-12].
Adherence to ART is a major determinant of virological
outcome [3,13,14] and in industrialized countries other
baseline factors influencing virological response have
included disease stage [15], viral load [15,16], and previ-
ous exposure to ART[15], although associations with
baseline CD4 count and viral load are not consistent
[17,18]. Determinants of virological outcomes, and the
effect of differences in the health delivery system on out-
comes, have not been studied in detail in resource limited
settings. Understanding these issues is important to guide
the development of effective ART programmes.
Another obstacle to effective HIV care in resource-limited
countries is limited access to laboratory facilities to mon-
itor the virological and immunological markers that are
considered the standard of care in wealthy nations. For
middle-income settings, where there is limited laboratory
support, data are needed to inform guidelines on how
best to use scarce resources for laboratory monitoring; for
example to decide at what point after starting ART it is
most useful to measure viral load to ensure the best out-
comes for patients.
We report risk factors for suboptimal virological outcome
at 12 months among HIV-infected adults receiving ART in
a workplace-based HIV care programme in South Africa.
Methods
ART clinic protocol
This workplace-based HIV care programme, primarily
serving the mining workforce, has been described in detail
elsewhere [19]. The programme was designed by Aurum
Institute and has been implemented at workplace sites in
Southern Africa, which vary from large hospital clinics
through occupational health centres to general practition-
ers' offices. Standard guidelines were developed for the
programme and are used at all sites; these provide guid-
ance on all aspects of HIV care including provision of
counseling, antiretroviral therapy guidelines, clinical and
laboratory monitoring and opportunistic infection
prophylaxis. ART is supplied either through a central
pharmacy which supplies named-patient medication to
sites via a courier, or through on-site pharmacies. Clinical
data are collected on standardized forms and entered into
a central database. Aurum staff provide training, based on
the programme guidelines, for clinic staff both prior to
programme initiation, and refresher training at intervals
afterwards. Individual sites determine where within their
health service the programme will be delivered, which
pharmacy system is used, and manage clinic staff.
Eligibility for ART is determined using the CD4 count and
World Health Organization (WHO) clinical stage, which,
at the time of this study, was based on the 1990 defini-
tions [20]: in brief, WHO stage 1 is asymptomatic infec-
tion, stage 2 is mild disease such as mucocutaneous
manifestations, stage 3 is moderately severe disease but
generally not defining AIDS (including pulmonary tuber-
culosis within the previous year) and stage 4 is severe dis-
ease including many AIDS-defining conditions.
Individuals are eligible for ART if they have HIV infection
and have a CD4 count <250 × 106/l regardless of World
Health Organization (WHO) stage of HIV disease; or are
in WHO clinical stage 3 with a CD4 count below 350 ×
106/l; or are in WHO clinical stage 4, regardless of CD4
count. Prior to ART initiation, ART-eligible individuals
have at least two clinic visits and participate in a prepara-
tory three-step counselling process. Standardised drug reg-
imens are used: the first line regimen is zidovudine,
lamivudine and efavirenz, and the second line regimen is
abacavir, didanosine and lopinavir-ritonavir. Single drug
substitutions are made if necessary, for example, stavu-
dine is substituted for zidovudine for patients with anae-
mia, and nevirapine for efavirenz for women of child-
bearing potential. Other changes to the regimens can be
made after consultation with the clinical HIV consultants.
All ART starts, changes and stops are recorded by the clini-
cian on a form which details the regimen and the reason
for the decision.
At every clinic visit, data including self-reported adherence
to ART, WHO clinical stage and weight are recorded. Indi-
viduals reporting less than perfect adherence are offered
additional counseling. In accordance with clinic guide-
lines, CD4 count and plasma viral load are measured atPage 2 of 8
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months thereafter.
A pharmacy register records when ART prescriptions are
received and when prescriptions are collected from the
pharmacy. If ART is not collected, clinic staff are notified,
and the participant is invited back to the clinic for further
evaluation and counselling.
Study design and participants
We analysed virological outcomes on ART using clinic
data as an observational cohort. We included HIV-
infected adults who were previously ART-naïve, who
started ART before 1 July 2004 from nine companies (39
sites) who have at least 10 patients within their HIV care
programme. We included follow-up data available up to
31 March 2006: thus all included individuals had the
opportunity for at least 12 months of follow-up. The ART
start date was defined as the date ART was first prescribed.
For individuals who left the programme due to end of
employment, death or other reasons, exit dates were
determined using treatment stop forms completed by
clinic physicians. Individuals who died were not consid-
ered as treatment failures, consistent with other reports
[21] because most deaths in developing country ART pro-
grammes occur soon after ART start [22], before virologi-
cal failure is likely to have occurred. Individuals who were
lost to follow-up during the study were investigated to
determine the date of and reason for discontinuation. The
main analysis included all individuals with an HIV-1 RNA
measurement at 12 months, and individuals who
switched to second-line treatment prior to the 12 month
visit, who were considered as having virological failure at
12 months. A further analysis also included individuals
remaining in the workforce but who had stopped ART
prior to the 12 month visit, with these individuals
assumed to have virological failure at 12 months. Individ-
uals who had discontinued because they left the work-
force were excluded from all risk factor analysis. HIV-1
RNA levels at 6 weeks, 6 and 12 months were defined as
the measurement taken between 28–120 days, 121–240
days and 300–450 days following initiation of ART,
respectively. If there was more than one measurement in
the interval the HIV-1 RNA taken closest to respective visit
was used.
Laboratory protocol
Plasma HIV-1 RNA levels were determined at one central
laboratory using the Versant HIV-1 RNA 3.0 assay (bDNA)
(Bayer Corporation, Tarrytown, New York, USA.), meas-
urement range 50–500,000 copies/ml. CD4 counts were
determined using either FACSCOUNT (BD Biosciences,
San Jose, California) or FACSCalibur (BD Biosciences, San
Jose, California).
Data management and statistical analysis
Data were entered into a password protected Access data-
base (Microsoft Office, 2000) and verified. Analysis was
carried out using STATA v.9 (Stata Corporation, College
Station, Texas, USA).
Plasma HIV-1 RNA concentrations were analysed using
the log10 scale; values above or below the quantifiable
range were assigned values at the respective limits of the
assay. Risk factors for suboptimal virological outcome (>=
400 HIV-1 RNA copies/ml) at 12 months were analysed
by logistic regression. Risk factors considered were prima-
rily baseline (at start of ART) variables, but we also looked
at virological response and self-reported adherence at six
weeks, because this is the first point after ART start at
which viral load is measured routinely and represents an
early point at which interventions to promote adherence
could be implemented if required. When analyzing the
association with self-reported adherence to ART at the six-
week visit, because only about 10% of individuals
reported missing any ART, we categorized adherence as
perfect (100% reported adherence in last 3 days) and non-
perfect (<100%). Factors with a P value of < 0.10 were
considered for the multivariable analysis. When consider-
ing programme delivery site as a risk factor, sites where
greater than 100 individuals had started ART were consid-
ered as separate entities (sites A, B and C, each of which
serves individuals working for a single company). Sites
which were too small to be analyzed separately were
grouped; those belonging to one company were consid-
ered as site D and all other sites as site E, on the basis that
policy differed by company regarding implementation of
the ART programme on issues such as pharmacy arrange-
ments and clinic staffing levels. The likelihood ratio test
was used to assess associations between risk factors and
outcome.
Ethical considerations
This study was approved by the Research Ethics Commit-
tees of Anglogold Health Service, South Africa and the
London School of Hygiene & Tropical Medicine, UK.
Results
A total of 1760 individuals had started ART before 1st July
2004, satisfied the other inclusion and exclusion criteria
and were therefore eligible for the analysis. The median
age was 41 years (range 21–66 years) and 97% (1701/
1760) were male, reflecting the gender distribution of the
workforce. Of the 1760 individuals, 175 (9.9%) and 213
(12.1%) had died or left the workforce before the 12
month follow-up, respectively, and 200 (11.4%) stopped
ART before 12 months (Figure 1). Of the remaining 1172
individuals, 81.3% (953/1172) either had a viral load
measurement at 12 months or started second line therapy
prior to the 12 month visit, and data are subsequentlyPage 3 of 8
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at 12 months, baseline CD4 counts, viral load and 6 week
viral loads were similar in the 219 individuals who did
not have viral load measured at 12 months compared
with the 953 who did have viral load measured at 12
months. The median time from initiation of ART to the 6
week HIV-1 RNA measurement was 7.1 weeks (inter-quar-
tile range [IQR]: 6.3–8.9). For the 6 and 12 month HIV-1
RNA measurements the median times from initiation of
ART were 5.9 (IQR: 5.6–6.3) and 12.0 (IQR: 11.4–12.6)
months, respectively.
The age and gender distribution of individuals with a viral
load result at 12 months was similar to the overall group
(median age 41 years, 96% male). At the time of starting
ART the median weight was 63 kg (IQR: 57–69 kg),
median CD4 count was 156 × 106/l (IQR: 86–230 × 106/
l) and 73.0% of individuals were in WHO stage 3 or 4
(Table 1). There were differences in baseline characteris-
tics between sites, notably for WHO stage and CD4 count.
At 6 weeks, 6 and 12 months the median (IQR) increases
in CD4 count from baseline were 76 (21–142), 92 (28–
162) and 107 (33–216) × 106/l, respectively. By 12
months the median gain in weight was 3 kg (IQR: -1 to 7
kg). At 6 weeks 88.6% (669/755) of individuals had a
greater than 1 log decrease in viral load, and at 6 weeks, 6
and 12 months 81.2% (651/802), 78.2% (594/760) and
71.5% (681/953) of individuals had virological suppres-
sion (defined as viral load < 400 copies/ml), respectively.
Of the 656 individuals who had viral load measurements
at 6 weeks, 6 and 12 months 63.4% (n = 416) had sup-
pressed viral load levels at all three time points.
Table 2 summarises univariable risk factors for a subopti-
mal virological outcome at 12 months. Older age, higher
viral load, lower weight and WHO stage 3 or 4 at baseline,
less than a 1 log decrease in viral load at 6 weeks and less
than 100% adherence at 6 weeks were all associated with
an increased odds of suboptimal virological outcome at
12 months. Large differences in virological response at 12
months were also observed by site of delivery; the percent-
age with viral load >= 400 copies/ml at 12 months ranged
from 18–39% across the five sites.
The multivariable analysis is reported in Table 2. Virolog-
ical response and self-reported adherence at six weeks
were included in the same model as the data suggests
these variables may capture different information (Table
3). Amongst n = 719 patients with both viral load and
adherence measured at 6 weeks 18% had differing results;
10% (72/719) reported 100% adherence but had <1 log
decrease in viral load, whereas 8% (60/719) reported
<100% adherence but had satisfactory virological
response. Site of ART delivery, WHO stage, viral load at
baseline, unsatisfactory decrease in viral load at six weeks
and less than 100% self-reported adherence at six weeks
were all independent risk factors for suboptimal virologi-
cal outcome.
A further analysis was carried out including the 200 indi-
viduals who had stopped ART prior to the 12 month visit.
Reasons for stopping ART included poor patient adher-
ence or adverse event (63%; n = 126), patient request
(11%; n = 23), failure by patient to collect ART prescrip-
tion (20%; n = 39) and 6% for other reasons. Assuming
these additional 200 individuals had suboptimal virolog-
ical outcome at 12 months 59.1% would have virological
suppression at 12 months. Risk factors for poor outcome
were similar to the analysis reported in Table 2.
Discussion
The earliest reports from ART programmes in low-income
countries were from programmes managed by non-gov-
ernmental organizations. In their early phases when ART
availability was limited, some programmes had stringent
entry criteria, requiring good adherence to visits and to
preventive therapy before ART was started [7]. These entry
criteria are likely to have resulted in a clinic population
Flow diagram showing cohort constructionigure 1
Flow diagram showing cohort construction.
N= 1760 
started ART before 01 July 04 and 
satisfy other inclusion/exclusion criteria 
N=  213 (12.1% )  
left the workforce during the first 12 months
N= 200 (11.4% )  
stopped ART during the first 12 months 
N= 175 (9.9% )   
died during the first 12 months 
N= 219 (12.4% )   
no HIV viral load measurement at 12 months 
and not died, stopped ART or left workforce by 
12 months 
Main analysis: N= 953 
 
Individuals who have an HIV viral load 
measurement at 12 months (n= 932) or 
who had started second line therapy 
prior to the 12 month visit (n= 21). 
ART: antiretroviral therapy Page 4 of 8
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tional consequence may have been very high mortality
among individuals waiting to start treatment [23]. In our
programme the criteria for offering ART were medical
need, with no prerequisite to demonstrate adherence,
making it more similar to routine programmes in indus-
trialized countries. Virological outcomes in those who
had a 12 month blood sample taken were similar to those
reported from clinic cohorts in the United States [24], but
losses from our programme are higher than reported from
such cohorts, and this is a limitation of our study.
We can distinguish two main reasons for losses from our
programme; individuals who have left the workforce,
which may not relate to virological outcome, and those
remaining in the workforce who have stopped ART, who
may be assumed to have treatment failure. The reasons for
default have been briefly reported elsewhere [25] and are
currently being investigated in detail. From patient inter-
view the reasons cited for leaving the programme
included use of traditional medicines, side effects and not
being convinced of the benefits of treatment. A systematic
review of patient retention in ART programmes in sub-
Saharan Africa found that the percentage of patients
retained at 12 months from initiation of ART (where
retention was defined as patients known to be alive and
receiving ART) varied between 49%–90.3% (median
76%) [26]. Based on this definition patient retention in
our study was comparable at 67%.
As ART roll out progresses, retention within programmes
will become a key issue determining long-term success.
Among patients in our programme who had a viral load
measured, 71.5% had suppressed viral load at 12 months
following initiation of ART. Using the same analysis
approach other South African studies have reported better
outcomes [7,9] whilst a small study in Senegal reported
61.9% with viral load < 500 copies/ml at 12 months [10].
We found that high baseline viral load and more
advanced WHO stage were risk factors for a suboptimal
virological outcome at 12 months. A fall in viral load of
less than one log at 6 weeks predicted a suboptimal viro-
logical outcome at 12 months, consistent with reports
from industrialized countries [15,16,27,28], as did
reported less than perfect adherence at six weeks. In our
setting there was very little ART use prior to the start of this
cohort and hence transmitted resistance among our par-
ticipants is unlikely; poor virological response is most
likely to be due to poor adherence. Suboptimal adherence
should be identified as early as possible, so that additional
support can be provided, aiming to minimize the risk of
ART resistance developing. In resource-limited settings, if
it is possible to measure baseline viral load, an early meas-
ure of viral load on treatment (for example at four to six
weeks) would be arguably more valuable than at the six
month visit as suggested, for example, in South African
guidelines [29]. Self-reported adherence was also a strong
predictor of outcome at 12 months which may be useful
if viral load measurements cannot be done.
Table 1: Baseline characteristics of the cohort overall and by ART delivery site
Overall By ART delivery site
Site A Site B Site C Site D Site E
n 953 165 238 198 145 207
Age (years) Median 41 38 39 44 39 44
IQR 35–46 34–41 34–44 39–48 32–46 37–49
Sex Male (%) 95.9 97.0 97.1 99.0 91.0 94.2
CD4 (× 106/l) Median 156 177 140 160 131 169
(IQR) 86–230 106–280 77–205 83–250 88–185 101–222
WHO stage* 1–2 (%) 27.0 16.0 12.8 28.4 38.8 45.7
3 46.2 36.4 47.7 53.6 45.5 45.7
4 26.8 47.5 39.6 18.0 15.7 8.7
Viral load (copies/ml) <= 10,000 (%) 20.1 20.1 20.5 18.1 16.7 24.0
10,001–100,000 49.7 46.5 50.5 51.3 48.6 50.5
>100,000 30.3 33.3 29.0 30.6 34.8 25.5
Weight (kg) Median 63 64 65 61 60 65
IQR 57–69 59–69 59–70 56–68 52–67 60–73
ART regimen COM/EFV (%) 94.1 96.4 94.5 97.0 86.9 94.2
ART = antiretroviral therapy; IQR = interquartile range; WHO = World Health Organization; COM = Combivir; EFV = Efavirenz
* clinical staging of HIV disease (see methods for definition).Page 5 of 8
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Table 2: Univariable and multivariable associations for suboptimal viral load response (>= 400 copies/ml) at 12 months














Sex Male 914 258 (28) 1 - 0.31 1 0.52
Female 39 14 (36) 1.42 0.73–2.78 1.38 0.53–3.61
Age – grouped 
(years)
<35 225 53 (24) 1 0.16 1 0.33
35–39 199 51 (26) 1.12 0.72–1.74 1.50 0.83–2.71
40–44 227 70 (31) 1.45 0.95–2.20 Pt = 0.01 1.43 0.82–2.52
45–49 166 53 (32) 1.52 0.97–2.38 1.89 1.04–3.43
>= 50 136 45 (33) 1.60 1.00–2.57 1.50 0.77–2.93
Site Site A 165 35 (21) 1 - <0.001 1 <0.001
Site B 238 44 (18) 0.84 0.51–1.38 0.71 0.39–1.32
Site C 198 78 (39) 2.41 1.59–3.86 2.38 1.32–4.31
Site D 145 49 (34) 1.90 1.14–3.15 1.80 0.92–3.50
Site E 207 66 (32) 1.74 1.08–2.79 1.70 0.88–3.31
WHO stage** 
(n = 55 missing)
1–2 242 52 (21) 1 - 0.02 1 0.007
3 415 131 (32) 1.69 1.16–2.44 2.08 1.28–3.34
4 241 66 (27) 1.38 0.91–2.09 2.03 1.14–3.62
CD4 count at baseline 
(× 106/l) (n = 45 Missing)
<= 50 126 37 (29) 1 - 0.5
51–100 136 46 (34) 1.23 0.73–2.07
101–200 332 95 (29) 0.96 0.61–1.51
201–350 273 70 (26) 0.83 0.52–1.33
> 350 41 13 (32) 1.12 0.52–2.39
Viral load at baseline 
(copies/ml) (n = 61 missing)
<= 10,000 179 36 (20) 1 0.02 1 <0.001
10,001– 443 134 (30) 1.72 1.13–2.62 3.63 1.88–7.00
100,000 270 85 (31) 1.83 1.17–2.85 3.54 1.79–7.00
>100,000
Weight (kg) 
(n = 77 missing)
<= 50 54 22 (41) 1 - 0.02
51–60 285 90 (32) 0.67 0.37–1.22
61–70 349 83 (24) 0.45 0.25–0.82 Pt = 0.007
>70 185 46 (25) 0.48 0.25–0.91
ART regimen COM/EFV 897 249 (28) 1 - 0.04
other 56 23 (41) 1.81 1.04–3.15
<1 log decrease in viral  
load at six weeks
(n = 198 missing)
No 669 157 (23) 1 - <0.001 1 <0.001
Yes 86 40 (47) 2.84 1.79–4.49 4.71 2.56–8.68
Self-reported adherence 
at 6 weeks 
(n = 73 missing)
100% 784 204 (26) 1 - <0.001 1 <0.001
<100% 95 43 (45) 2.35 1.52–3.63 3.50 1.92–6.35
* P-value from likelihood ratio test; Pt = P-value for linear trend
** clinical staging of HIV disease (see methods for definition).
WHO = World Health Organization; ART = antiretroviral therapy; COM = Combivir; EFV = Efavirenz
BMC Infectious Diseases 2008, 8:93 http://www.biomedcentral.com/1471-2334/8/93Our programme provides an unusual opportunity to
investigate the influence of health facility level, as well as
individual level, factors on ART outcomes. Site was an
important determinant of virological outcome which per-
sisted after adjustment for individual factors. Given that
all sites used the same clinical guidelines, criteria for start-
ing ART, counseling protocols and drug regimens, it is
interesting that site had such a large effect on the proba-
bility of achieving virological suppression. With relatively
few large sites to compare we cannot formally investigate
at the health facility level which may influence virological
outcomes. However our experience suggests some factors
which may be important include long waiting times for
clients (both in clinics and in pharmacy); using staff who
do not have specialized training in HIV care; failure to
contact individuals who do not attend clinic and lack of
communication between pharmacy and clinic staff if ART
is not collected. We plan to explore these issues in further
work, including comparison of costs at different clinic
sites.
Conclusion
In conclusion, in this cohort of adults starting ART in
South Africa, the strongest independent predictors of viro-
logical outcome at 12 months were the decrease in viral
load and self-reported adherence at six weeks. In settings
with limited access to viral load measurements, the viro-
logical response would be more usefully determined at
this point rather than later, so that appropriate interven-
tions can be implemented. Self-reported adherence at six
weeks was also an independent predictor of outcome.
Health system factors have an important influence on
virological outcomes; this needs further investigation to
guide implementation of effective ART programmes.
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